NICD3 mediates pro-angiogenic effects through SMAD3/TGFBI axis in colorectal cancer
Rui An, Ruihao Yu, Xinxin Wen, Qingyang Ma, Kelei Mao, Qi Zhang, Liyuan Mao, Xiaoyan Feng, Fang Xin, Ping Liu, Yijia Wang, Jiaqi Zhang, Haixia Huang, Xiaodong Yan, Wei Wang · 2026
Read NICD3 mediates pro-angiogenic effects through SMAD3/TGFBI axis in colorectal cancer by Rui An, Ruihao Yu, Xinxin Wen, Qingyang Ma, Kelei Mao, Qi Zhang, Liyuan Mao, Xiaoyan Feng, Fang Xin, Ping Liu, Yijia Wang, Jiaqi Zhang, Haixia Huang, Xiaodong Yan, Wei Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13493961.txt.
Description
Rui An leads a fifteen-author team exposing in 2026 a blood vessel growth circuit that makes the nastiest subtype of colorectal cancer so aggressive. The mesenchymal subtype shrugs off standard vessel-blocking drugs, so the team hunted for an alternative vascular engine and landed on NOTCH3, a signaling protein enriched in these tumors. Patient samples, cell cultures, and mouse tumors traced what it switches on.
The activated protein partners with a transcription factor to order production of TGFBI, a secreted factor that drives endothelial cells to build tubes and migrate. Tumor vessel density in stage four patients tracked the protein's levels, confirming clinical relevance. Screening then found hesperidin, a citrus flavonoid, binding the secreted factor tightly enough to cancel the vessel growth and slow tumors in animals, a candidate precision therapy.
Catalog record
| CREATOR | Rui An, Ruihao Yu, Xinxin Wen, Qingyang Ma, Kelei Mao, Qi Zhang, Liyuan Mao, Xiaoyan Feng, Fang Xin, Ping Liu, Yijia Wang, Jiaqi Zhang, Haixia Huang, Xiaodong Yan, Wei Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58161 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |